PDCD1 and neoplasm: Strategies to tailor inhibitory receptor disruption in tumor-specific cellular products have been proposed to overcome these limitations, but are mainly focused on PD-1- or CTLA-4- disrupted cells tested in short-term anti-tumor responses (23–31).